Food Allergy, Hypersensitivity, Hypersensitivity, Food, Peanut Allergy, Peanut Hypersensitivity
Conditions
Keywords
Food Allergy, Hypersensitivity, Peanut, Food Hypersensitivity, Allergy, Food
Brief summary
Food allergy is a serious public health concern that causes potentially-life threatening reactions in affected patients. The prevalence of food allergy in the United States (U.S.) has increased substantially and now affects 15 million patients:4-8% of children (6 million children, 30% with multiple food allergies) and about 9% of adults. This is a prospective Phase 2, multi-center, multi-allergen OIT study in participants with proven allergies to 2 or 3 different foods in which one must be peanut. The intent-to-treat population in the clinical study will be 110 participants, ages 4 to 55 years with a history of multiple food allergies of 2 to 3 different foods including peanut. Allergy will be confirmed by food allergen (FA)-specific Immunoglobulin E (IgE) levels or positive Skin Prick Test (SPT). Enrolled participants must be positive during the Double-blind Placebo-controlled Food challenge (DBPCFC) at or before the 300 mg protein (444 mg cumulative) dosing level of FA proteins.
Detailed description
This is a prospective Phase 2, multi-center, multi-allergen OIT study in participants with proven allergies to 2 or 3 different foods in which one must be peanut. The total population will be 110 participants, ages 4 to 55 years that present with a history of multiple food allergies of 2 or 3 different foods including peanut, food-allergen (FA)-specific Immunoglobulin E (IgE) levels or positive Skin Prick Test (SPT). Enrolled participants must react positively during DBPCFCs at or before the 300 mg (444 mg cumulative) dosing level of FA proteins of 2 or 3 allergens in which one must be a peanut. There will be three study cohorts, all will be double-blinded: Cohort A (50 participants) will be treated with omalizumab for 8 weeks followed by 24 weeks of treatment with placebo for dupilumab. Cohort B (50 participants) will be treated with omalizumab for 8 weeks, followed by 24 weeks of treatment with dupilumab. Cohort C (10 participants) will be treated with placebo for omalizumab for 8 weeks followed by 24 weeks treatment with dupilumab. All participants will receive multi-allergen OIT for peanut plus one or two additional protocol-specified foods from week 8 through week 32.
Interventions
DRUGOmalizumab
Omalizumab is injected every 2 or 4 weeks
DRUGDupilumab
Dupilumab is injected every 2 or 4 weeks combination, or placebo.
Placebo for dupilumab is injected every 2 or 4 weeks
Placebo for omalizumab is injected every 2 or 4 weeks
Sponsors
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)
Food Allergy Research & Education
Harvard School of Public Health (HSPH)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Intervention model description
This is a prospective Phase 2, multi-site, multi-allergen OIT in participants with proven allergies to 2 or 3 different foods in which one must be peanut. Our intent to treat population will be 110 participants, ages 4 to 55 years with a history of multiple food allergies of 2 or 3 different foods including peanut. Allergy will be confirmed by FA-specific IgE levels and positive skin prick test (SPT). Enrolled participants must be positive during the DBPCFCs at or before the 300 mg (444 mg cumulative) dosing level of FA proteins.
Eligibility
Sex/Gender
ALL
Age
4 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Age 4 through 55 years (inclusive). * Clinical history of peanut allergy and 1 or 2 additional foods from the following foods: milk, almond, shellfish, fish, cashew, hazelnut, egg, walnut, sesame seeds, soy, and wheat. Allergy to milk and egg is defined as unable to tolerate both cooked and uncooked forms. * Positive allergy test determined by: * ImmunoCAP serum IgE level \>4 kilo Units of allergen per Liter (kUA/L) for each allergen within the past 12 months OR * Skin prick test (SPT) ≥6 mm wheal diameter to each allergen. * A clinical reaction during a DBPCFC to small doses of food defined as a cumulative dose of =/\<444 mg food protein. * No clinical reaction observed during the placebo (oat) challenge. * Subject and/or parent guardian must be able to understand and provide informed consent. * Written informed consent from adult participants. * Written informed consent from parent/guardian for minor participants. * Written assent from minor participants as appropriate (e.g., at and above the age of 7 years). * Use of effective birth control by female participants of childbearing potential.
Exclusion criteria
* History of cardiovascular disease, including uncontrolled or inadequately controlled hypertension. * Individuals less than 15 kg in weight at start of the study * History of severe anaphylaxis to participant-specific foods that will be used in this study, defined as neurological compromise or requiring intubation. * History of chronic disease (other than asthma, atopic dermatitis or allergic rhinitis) that is, or is at significant risk of becoming, unstable or requiring a change in chronic therapeutic regimen. * History of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD), symptoms of dysphagia (e.g., difficulty swallowing, food "getting stuck"), or recurrent gastrointestinal symptoms of undiagnosed etiology. * Severe asthma (NAEPP EPR-3 Medication Criteria Steps 5 or 6) * Mild or moderate asthma (NAEPP EPR-3 Medication Criteria Steps 1-4), if uncontrolled or difficult to control. * Uncontrolled asthma as evidenced by: * FEV1 \< 80% of predicted, or ratio of Forced Expiratory Volume in 1 second (FEV1) to forced vital capacity (FEV1/ Forced Vital Capacity (FVC)) \< 75% of predicted, with or without controller medications (only for age 6 or greater and able to do spirometry reliably. If unable to do spirometry, Peak Expiratory Flow (PEF) of \>80% is acceptable) or; * One overnight admission to a hospital in the past year for asthma or; * Emergency room (ER) visit for asthma within six months prior to screening. * Inability to tolerate biological (antibody) therapies. * Use of immunomodulator therapy (not including corticosteroids). * Use of beta-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARB) or calcium channel blockers. * Current participation or within the last 4 months in any other interventional study. * Pregnancy or lactation. * Allergy to oat (placebo in DBPCFC). * Use of investigational drugs within 16 weeks of participation. * In build up phase of immunotherapy for aeroallergens or venom.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Success Rates of Passing a Peanut Double-Blind Placebo Controlled Food Challenge (DBPCFC) | 44 weeks | Success is defined as passing a cumulative dose of \>=1,043 mg at the Week 44 DBPCFC if the subject has no or mild objective reactions. The primary endpoints would be compared between cohort A and cohort B. Outcome measures (rates) are presented as the percent of participants who passed, with the additional detail of the counts of participants who pass, and the participants who were analyzed. |
| The Success Rates of Passing a DBPCFC to Peanut and at Least One Other FA | 44 weeks | Success is defined as passing a cumulative dose of \>=1,043 mg at the Week 44 DBPCFC if the subject has no or mild objective reactions. The primary endpoints would be compared between cohort A and cohort B. Outcome measures (rates) are presented as the percent of participants who passed, with the additional detail of the counts of participants who pass, and the participants who were analyzed. |
| The Success Rates of Passing a DBPCFC to Peanut and Two Other FAs | 44 weeks | Success is defined as passing a cumulative dose of \>=1,043 mg at the Week 44 DBPCFC if the subject has no or mild objective reactions. The primary endpoints would be compared between cohort A and cohort B. Outcome measures (rates) are presented as the percent of participants who passed, with the additional detail of the counts of participants who pass, and the participants who were analyzed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Participants Who Successfully Pass DBPCFCs to a Cumulative Dose of >=1,043 mg Protein to 1, 2, or 3 FAs When Applicable at Week 44 | 44 weeks | Outcome measures (rates) are presented as the percent of participants who passed, with the additional detail of the counts of participants who pass, and the participants who were analyzed. |
| Proportion of Participants Who Successfully Pass DBPCFCs to a Cumulative Dose of ≥2,043 mg to 1, 2, or 3 FAs When Applicable at Week 32 | 32 weeks | Outcome measures (rates) are presented as the percent of participants who passed, with the additional detail of the counts of participants who pass, and the participants who were analyzed. |
| Proportion of Participants Who Pass DBPCFCs for Each FA at a Cumulative Dose of ≥1,043 mg, ≥2,043 mg, or ≥4,043 mg at Week 32 and/or Week 44. | week 32 and/or 44 | Outcome measures (rates) are presented as the percent of participants who passed, with the additional detail of the counts of participants who pass, and the participants who were analyzed. |
| Proportion of Participants Who Have a 10-fold Change in the Cumulative Tolerance Dose for Each FA at Weeks 32 and/or Week 44, Compared to Baseline | Baseline and week 32 and/or 44 | Outcome measures (rates) are presented as the percent of participants who had a 10-fold change, with the additional detail of the counts of participants who had that change, and the participants who were analyzed. |
Countries
United States
Contacts
STUDY_DIRECTORRebecca S Chinthrajah, M.D.
Sean N Parker Center for Allergy and Asthma Center at Stanford
Participant flow
Pre-assignment details
130 participants were consented and screened for eligibility; 108 participants were randomized to receive biologics treatment/placebo, Oral Immunotherapy (OIT) and Double-Blind, Placebo-Controlled Food Challenge (DBPCFC)
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 13.08 Years STANDARD_DEVIATION 7.22 |
| Atopic Disorder Allergic Rhinitis | 32 Participants |
| Atopic Disorder Asthma | 31 Participants |
| Atopic Disorder Atopic Dermatitis | 9 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 7 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 98 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 3 Participants |
| Number of Allergens 2 food allergens | 18 Participants |
| Number of Allergens 3 food allergens | 31 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 37 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 28 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 2 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race (NIH/OMB) White | 18 Participants |
| Region of Enrollment United States | 10 Participants |
| Sex: Female, Male Female | 16 Participants |
| Sex: Female, Male Male | 73 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 49 | 0 / 49 | 0 / 10 |
| other Total, other adverse events | 34 / 49 | 39 / 49 | 7 / 10 |
| serious Total, serious adverse events | 0 / 49 | 1 / 49 | 1 / 10 |
Outcome results
None listed